OncoHost's groundbreaking research at AACR 2026: Unlocking the secrets of aging and immunotherapy
OncoHost, a technology company at the forefront of precision oncology, is set to present groundbreaking research at the American Association for Cancer Research (AACR) Annual Meeting 2026. The focus? Unraveling the complex relationship between biological aging and immunotherapy outcomes across various cancer types.
In my opinion, this research is a game-changer. It challenges the traditional tumor-centric approach and highlights the importance of systemic aging in cancer biology. By quantifying biological aging across the entire body, OncoHost is opening a new frontier in our understanding of cancer progression and treatment response.
The study, titled 'Proteomic aging biomarkers predict survival in immunotherapy-treated tumors', utilizes plasma proteomics to delve into the intricate relationship between aging and cancer. By analyzing deep plasma proteomic profiles from patients with metastatic solid tumors, including NSCLC, SCLC, RCC, and melanoma, alongside healthy controls, the research reveals fascinating insights.
One of the key findings is the significant elevation of biological age in cancer patients compared to healthy individuals. The 'age gap' is particularly striking in lung cancer (NSCLC and SCLC) and renal cell carcinoma (RCC), indicating a strong correlation between aging and cancer progression. This finding is not just intriguing but also has profound implications for treatment strategies.
What makes this research even more compelling is the link between immune-specific aging and immunotherapy benefit. The study demonstrates that patients with a high immune age gap, indicating a more aged immune system, have significantly shorter overall survival when treated with immune checkpoint inhibitors. This correlation is especially pronounced in melanoma, where the effect is most pronounced, and less evident in SCLC, possibly due to differences in tumor immunogenicity.
OncoHost's CEO, Ofer Sharon, emphasizes the significance of this shift in perspective. By moving beyond tumor-centric thinking and considering the body's overall aging process, OncoHost is unlocking a new layer of insight into cancer treatment. This approach has the potential to revolutionize how we guide immunotherapy, ultimately leading to more informed treatment decisions and improved patient outcomes.
The presentation at AACR 2026, titled 'Proteomic aging biomarkers predict survival in immunotherapy-treated tumors', will be a pivotal moment in the field. It will showcase how OncoHost's PROphet® platform, a plasma-based proteomic pattern analysis tool, can provide crucial guidance on first-line immunotherapy decision-making. This technology has already demonstrated its clinical utility in NSCLC, significantly impacting overall survival.
In conclusion, OncoHost's research at AACR 2026 is a testament to the power of innovation in precision medicine. By exploring the intricate relationship between aging and immunotherapy, they are paving the way for a more personalized and effective approach to cancer treatment. This research not only advances our scientific understanding but also holds the promise of transforming patient care and outcomes.
